Skip to main content

Drug-Related Infant Mortality Increased Significantly From 2018 to 2022

Medically reviewed by Carmen Pope, BPharm. Last updated on June 19, 2024.

By Lori Solomon HealthDay Reporter

WEDNESDAY, June 19, 2024 -- Drug-related infant mortality increased significantly from 2018 to 2022, according to a study published online May 22 in the Journal of Perinatal Medicine.

Panagiota Kitsantas, Ph.D., from Florida Atlantic University in Boca Raton, and colleagues used data from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research to explore temporal trends in drug-related infant deaths in the United States from 2018 to 2022.

The researchers found a significant 2.2-fold increase in drug-involved infant mortality during the study period. Compared with the neonatal period, drug-involved infant deaths were more likely to occur in the postneonatal period, defined as ages 28 to 364 days (81.4 percent). The most common underlying causes of death included assault (homicide) by drugs, medicaments and biological substances (35.6 percent), followed by poisoning due to exposure to narcotics and psychodysleptics (hallucinogens; 15.6 percent). The most common multiple causes of drug-involved infant deaths included psychostimulants with abuse potential of synthetic narcotics.

"Effective strategies to reduce drug-involved infant deaths will require preventing and treating maternal substance use disorders, enhancing prenatal care access, and addressing broader social and behavioral risk factors among vulnerable maternal and infant populations," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care

TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.